Merck's (MRK) Keytruda, in combination with Gilead's (GILD) Trodelvy, reduced the risk of disease progression or death by 35% compared with Keytruda and chemotherapy for the first-line treatment of patients with locally advanced or metastatic triple-negative breast cancer in a Phase 3 study, the companies announced on Saturday.
The Keytruda-Trodelvy combination resulted in a median progression-free survival of 11.2 months, up from 7.8 months when Keytruda was given in combination with chemotherapy in the 443-patient randomized trial, the companies said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.